Feasibility and therapeutic potential of [ 177 Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma.

Seyedeh Somayyeh BanihashemianMohammad Esmaeel AkbariElahe PirayeshGhasemali DivbandAbdolghafar Abolhosseini ShahrnoyReza NamiSeyed Mohammad MazidiMeysam Nasiri

Published in: European journal of nuclear medicine and molecular imaging (2024)

Lu]Lu-FAPI-2286 PTRT, utilized for diverse cancer types, exhibited favorable tolerability in sarcoma patients, with minimal side effects, long-lasting retention of the radiopeptide within the tumor, and promising therapeutic effects. Preliminary findings of this prospective study need to be confirmed through further clinical trials.

Keyphrases

clinical trial
squamous cell carcinoma
small cell lung cancer
papillary thyroid
open label
squamous cell
phase ii
lymph node metastasis